ClinicalTrials.gg
CompletedNCT07942987Updated Nov 17, 2026

Effects of Adjunctive N-Acetylcysteine and Curcumin on Helicobacter Pylori Eradication and Dyspeptic Symptoms: A Randomized Controlled Trial

A Phase 4 interventional study of Esomeprazole + Amoxicillin + Levofloxacin + Bismuth and N-acetylcysteine (NAC) 600 mg in HELICOBACTER PYLORI INFECTIONS, sponsored by University of Thi-Qar. Completed at 1 site in Iraq. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Thi-Qar · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2026, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Helicobacter pylori (H. pylori) is a bacterium that infects the stomach and may cause gastritis, peptic ulcer disease, and dyspeptic symptoms. Although antibiotic-based treatments are commonly used to eradicate the infection, treatment failure remains a clinical concern.

This randomized controlled trial evaluated whether adding N-acetylcysteine (NAC) or curcumin to standard treatment could improve H. pylori eradication and reduce dyspeptic symptoms.

A total of 150 adults with H. pylori infection were assigned to one of three groups: standard treatment alone, standard treatment plus NAC, or standard treatment plus curcumin. Standard treatment consisted of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days.

The primary outcome was H. pylori eradication, assessed using a 13C-urea breath test four weeks after treatment completion. Secondary outcomes included changes in dyspeptic symptoms measured using the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) and the occurrence of adverse effects.

02

Conditions studied

  • HELICOBACTER PYLORI INFECTIONS

Keywords

  • antibiotic resistance, curcumin, n-acetylcystein, eradication therapy
03

In context

Lead sponsor

University of Thi-Qar is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years.
  • Confirmed Helicobacter pylori infection by urea breath test or stool antigen test.
  • Presence of dyspeptic symptoms.

Exclusion criteria

Exclusion Criteria:

  • Use of antibiotics, proton pump inhibitors (PPIs), or nonsteroidal anti-inflammatory drugs (NSAIDs) within the previous 4 weeks.
  • Known allergies to the study medications.
  • Pregnancy or lactation.
  • Severe comorbid conditions, including hepatic, renal, or cardiac disease.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Active comparator
    Standard Therapy (Control Group)

    Participants in this arm received standard therapy consisting of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days, without adjunctive N-acetylcysteine or curcumin.

    Drug: Esomeprazole + Amoxicillin + Levofloxacin + Bismuth

  • Experimental
    Standard Therapy + N-Acetylcysteine (NAC)

    Participants in this arm received standard therapy consisting of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days, with adjunctive N-acetylcysteine.

    Drug: Esomeprazole + Amoxicillin + Levofloxacin + Bismuth · Drug: N-acetylcysteine (NAC) 600 mg

  • Experimental
    Standard Therapy + Curcumin

    Participants in this arm received standard therapy consisting of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days, with adjunctive curcumin.

    Drug: Esomeprazole + Amoxicillin + Levofloxacin + Bismuth · Drug: Curcumin (Turmeric)

Interventions

  • DrugEsomeprazole + Amoxicillin + Levofloxacin + Bismuth

    The standard treatment regimen consisted of esomeprazole, amoxicillin, levofloxacin, and bismuth administered orally for 14 days. This regimen was used in all three study arms, either alone or in combination with N-acetylcysteine or curcumin.

  • N-Acetylcysteine was administered orally as an adjunct to the standard treatment regimen for Helicobacter pylori eradication.

  • Curcumin was administered orally as an adjunct to the standard treatment regimen for Helicobacter pylori eradication.

06

What researchers measure

Primary outcomes

  1. Helicobacter pylori Eradication Rate

    The proportion of participants achieving successful Helicobacter pylori eradication, defined as a negative 13C-urea breath test (UBT) performed four weeks after completion of the 14-day treatment regimen. Eradication rates were compared among the three treatment groups.

    Time frame: 4 weeks after completion of treatment

Secondary outcomes

  1. Change in Dyspeptic Symptoms (SF-LDQ Score)

    Change in dyspeptic symptoms was assessed using the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ). The questionnaire evaluates indigestion, heartburn, acid regurgitation, and nausea. Total scores range from 0 to 32, with higher scores indicating greater symptom burden. Change was calculated as the post-treatment score minus the baseline score; negative values indicate symptom improvement.

    Time frame: Baseline and approximately 2 months after baseline

  2. Incidence of Treatment-Related Adverse Effects

    The proportion of participants reporting at least one adverse effect during the 14-day treatment period was assessed in each study group. Adverse effects were documented through patient follow-up and compared among the three treatment groups.

    Time frame: During the 14-day treatment period

07

Study locations

1 site
  • Dr. Faez Khalaf Abdulmohsen's Gastroenterology Clinic
    Nasiriyah, Thi-Qar, Iraq
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to patient confidentiality and privacy considerations. Only aggregated and anonymized study results will be reported in scientific publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Sep 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Jan 20, 2026
Primary completionActual
Sep 28, 2026
CompletionActual
Oct 15, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942987
Lead sponsor
University of Thi-Qar
Responsible party
Nabaa Mohsen (MSc Student, Department of Pharmacology, College of Pharmacy, University of Thi-Qar, University of Thi-Qar) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 20, 2026
Primary completion
Sep 28, 2026
Completion
Oct 15, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetylcysteine · Curcumin

Start the discussion